[go: up one dir, main page]

PE20130383A1 - Derivados del acido 1-amino-2-ciclopropiletilboronico - Google Patents

Derivados del acido 1-amino-2-ciclopropiletilboronico

Info

Publication number
PE20130383A1
PE20130383A1 PE2012001810A PE2012001810A PE20130383A1 PE 20130383 A1 PE20130383 A1 PE 20130383A1 PE 2012001810 A PE2012001810 A PE 2012001810A PE 2012001810 A PE2012001810 A PE 2012001810A PE 20130383 A1 PE20130383 A1 PE 20130383A1
Authority
PE
Peru
Prior art keywords
amino
acid
cyclopropylethylboronic
cyclopropyl
phenyl
Prior art date
Application number
PE2012001810A
Other languages
English (en)
Inventor
Paul E Fleming
Jing Li
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130383(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20130383A1 publication Critical patent/PE20130383A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DEL ACIDO 1-AMINO-2-CICLOPROPILETILBORONICO .DE FORMULA (I) DONDE: A ES UN ENTERO ENTRE 0 Y 2; P ES H O UN RADICAL DE BLOQUEO DE GRUPO; Ra2 ES HIDROGENO, ALIFATICO C1-C6, FLUOROALIFATICO C1-C6 ENTRE OTROS; Z 1 Y Z2 SON HIDROXI, ALCOXI, ARILOXI, ARALCOXI O FORMAN JUNTOS UN RADICAL DERIVADO DE AGENTE DE ACOMPLEJAMIENTO DE ACIDO BORONICO. SON COMPUESTOS PREFERIDOS: ACIDO((1R)-2-CICLOPROPIL-1-{[(2S)-3-FENIL-2-({[4-(PIRIDIN-2-ILOXI)FENIL]SULFONIL}AMINO)PROPANOIL]AMINO}ETIL)BORONICO, ACIDO{(1R)-2-CICLOPROPIL-1-[((2S)-2-{[(6-FENOXIPIRIDIN-3-IL)SULFONIL]AMINO}-3-FENILPROPANOIL)AMINO]ETIL}BORONICO; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE PROTEASOMA UTIL EN EL TRATAMIENTO DEL CANCER.
PE2012001810A 2010-03-31 2011-03-30 Derivados del acido 1-amino-2-ciclopropiletilboronico PE20130383A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31

Publications (1)

Publication Number Publication Date
PE20130383A1 true PE20130383A1 (es) 2013-04-24

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001810A PE20130383A1 (es) 2010-03-31 2011-03-30 Derivados del acido 1-amino-2-ciclopropiletilboronico

Country Status (26)

Country Link
US (3) US8513218B2 (es)
EP (1) EP2552216B1 (es)
JP (1) JP5933523B2 (es)
KR (1) KR20130036228A (es)
CN (3) CN106008570A (es)
AR (1) AR080863A1 (es)
AU (1) AU2011235227B2 (es)
CA (1) CA2794334C (es)
CL (1) CL2012002733A1 (es)
CO (1) CO6630162A2 (es)
CR (1) CR20120529A (es)
DO (1) DOP2012000257A (es)
EA (1) EA029521B1 (es)
EC (1) ECSP12012249A (es)
MA (1) MA34169B1 (es)
MX (1) MX2012011298A (es)
NZ (1) NZ602622A (es)
PE (1) PE20130383A1 (es)
PH (1) PH12012501943A1 (es)
RU (1) RU2012146101A (es)
SG (1) SG184222A1 (es)
TN (1) TN2012000465A1 (es)
UA (1) UA110612C2 (es)
UY (1) UY33314A (es)
WO (1) WO2011123502A1 (es)
ZA (2) ZA201207406B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008006090A (es) 2005-11-09 2008-10-23 Proteolix Inc Compuestos para inhibicion de la enzima.
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
KR20160086980A (ko) 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
KR101691093B1 (ko) 2008-06-17 2016-12-29 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
MY188960A (en) 2010-08-10 2022-01-14 Melinta Therapeutics Llc Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
KR20140114391A (ko) * 2011-12-22 2014-09-26 아레스 트레이딩 에스.에이. 알파-아미노 보론산 유도체, 선택적 면역프로테아좀 저해인자
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2015008628A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US20160250238A1 (en) 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
WO2015106200A2 (en) 2014-01-10 2015-07-16 Cornell University Dipeptides as inhibitors of human immunoproteasomes
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2015179443A1 (en) 2014-05-20 2015-11-26 Millennium Pharmaceuticals. Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
JP6758282B2 (ja) 2014-08-18 2020-09-23 コーネル・ユニバーシティーCornell University ヒト免疫プロテアソーム阻害剤としてのジペプチド模倣薬
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2905008T3 (es) 2015-10-15 2022-04-06 Univ Cornell Inhibidores de proteasomas y usos de los mismos
PL3478693T3 (pl) 2016-06-30 2021-12-13 Qpex Biopharma, Inc. Pochodne kwasu boronowego i ich zastosowania terapeutyczne
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2019075084A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ES2098484T3 (es) 1992-08-14 1997-05-01 Procter & Gamble Detergentes liquidos que contienen un acido alfa-amino-boronico.
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
EP0979096B1 (en) 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
AU735685B2 (en) 1997-12-16 2001-07-12 Cephalon, Inc. Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
JP5140222B2 (ja) 2000-02-29 2013-02-06 ブリストル−マイヤーズ スクイブ カンパニー 低用量エンテカビル製剤およびその使用
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP1355910B1 (en) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
WO2003059898A2 (en) 2002-01-08 2003-07-24 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
LT4008721T (lt) 2004-03-30 2024-03-25 Millennium Pharmaceuticals, Inc. Borono esterio ir rūgšties junginių sintezė
EP1898899A4 (en) 2005-07-05 2009-07-29 Tufts College INHIBITORS OF THE FIBROBLAST ATTACHMENT PROTEIN ALPHA
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
KR20150010802A (ko) 2007-08-06 2015-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR101691093B1 (ko) 2008-06-17 2016-12-29 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.

Also Published As

Publication number Publication date
AU2011235227B2 (en) 2016-09-08
MA34169B1 (fr) 2013-04-03
CN102892291A (zh) 2013-01-23
CN106008570A (zh) 2016-10-12
DOP2012000257A (es) 2012-11-15
US8703743B2 (en) 2014-04-22
EP2552216A1 (en) 2013-02-06
WO2011123502A1 (en) 2011-10-06
ZA201308086B (en) 2015-03-25
KR20130036228A (ko) 2013-04-11
US20110245203A1 (en) 2011-10-06
JP2013523760A (ja) 2013-06-17
CA2794334A1 (en) 2011-10-06
US9023832B2 (en) 2015-05-05
CN107266485A (zh) 2017-10-20
AU2011235227A1 (en) 2012-10-18
US8513218B2 (en) 2013-08-20
EA201290980A1 (ru) 2013-03-29
ECSP12012249A (es) 2012-11-30
PH12012501943A1 (en) 2017-08-23
MX2012011298A (es) 2012-11-06
CL2012002733A1 (es) 2013-01-25
CA2794334C (en) 2018-06-12
US20140011998A1 (en) 2014-01-09
US20140179631A1 (en) 2014-06-26
UA110612C2 (uk) 2016-01-25
CO6630162A2 (es) 2013-03-01
NZ602622A (en) 2015-01-30
EP2552216A4 (en) 2013-07-31
UY33314A (es) 2011-10-31
CR20120529A (es) 2013-01-11
EA029521B1 (ru) 2018-04-30
ZA201207406B (en) 2014-01-29
AR080863A1 (es) 2012-05-16
JP5933523B2 (ja) 2016-06-08
SG184222A1 (en) 2012-10-30
TN2012000465A1 (en) 2014-01-30
RU2012146101A (ru) 2014-05-10
EP2552216B1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
PE20130383A1 (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
BR112014015363A2 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
PE20100562A1 (es) Derivados policiclicos de indazol como inhibidores de erk
CA2875877C (en) Syk inhibitors
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PH12016502037B1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
NZ606001A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
NZ608120A (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
PE20141408A1 (es) Aminoquinazolinas como inhibidores de quinasa
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
MX361458B (es) Compuestos de pirimido-piridazinona y uso de los mismos.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12015502429A1 (en) Dicarboxylic acid compound
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
TR201902057T4 (tr) Tetrasiklin bileşikleri.
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
EA201370251A1 (ru) Производное камптотецина, способ получения такового, фармацевтическая композиция и ее применение
EA201190269A1 (ru) 2'-фторарабинонуклеозиды и их применение

Legal Events

Date Code Title Description
FC Refusal